Dr. Steve Lipkin is part of the Crazy 8 team studying a vaccine for childhood cancer predisposition syndromes.

Dr. Lipkin is Vice Chair for Research, Weill-Cornell Department of Medicine. His research laboratory uses massively parallel sequencing, computational biology, mouse models, cell culture and genomics to understand the contribution of genetics to, and mechanisms of, hereditary cancer genetic syndromes. He discovered and mechanistically characterized MLH3, a DNA mismatch repair gene colorectal polyposis and cancer predisposition gene. He has also identified or co-identified 6 B cell malignancy predisposition genes.

His lab was also the first to model human cancer cells in immune competent mice. He currently leads an NCI multi-institutional Center for Cancer Immunoprevention and is working on developing and validating precision prevention and precision therapies for patients with DNA repair deficient cancers.